Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.30 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22751618 | 0.93 | PKM (0.32) | PKMCNR1GPR55ALKBH5FTO | |
| SCHEMBL22751638 | 0.91 | PKM (0.34) | PKMCNR1GPR55MAPT | |
| SCHEMBL20689996 | 0.90 | BCHE (0.31) | BCHEACHELMNAMAPTSMN1; SMN2 | |
| SCHEMBL20689855 | 0.88 | LMNA (0.32) | BCHEACHELMNAMAPTSMN1; SMN2 | |
| SCHEMBL20689857 | 0.88 | LMNA (0.32) | BCHEACHELMNAMAPTSMN1; SMN2 | |
| SCHEMBL22751643 | 0.88 | PDK2 (0.32) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22751655 | 0.87 | MAPT (0.33) | BCHEACHELMNAMAPTSMN1; SMN2 | |
| SCHEMBL22751672 | 0.87 | KDM4E (0.32) | MAPT | |
| SCHEMBL22751711 | 0.85 | — | — | |
| SCHEMBL17915735 | 0.82 | PKM (0.37) | PKMCNR1GPR55LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10862050-B2 | Heterocyclic compound and organic electroluminescence device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10862050-B2 | Heterocyclic compound and organic electroluminescence device including the same | CCNT1, CCNL2, CCNA1 | BCHE 4177/4885ACHE 1746/4885PKM 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.